Join Growin Stock Community!

Geovax labs, inc.GOVX.US Overview

US StockHealthcare
(No presentation for GOVX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GOVX AI Insights

GOVX Overall Performance

GOVX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GOVX Recent Performance

1.88%

Geovax labs, inc.

0.05%

Avg of Sector

-0.31%

S&P500

GOVX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GOVX Key Information

GOVX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GOVX Profile

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

Price of GOVX

GOVX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-24.95
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.83
PB Ratio
0.56
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-24.95
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.83
PB Ratio
0.56
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is GOVX's latest earnings report released?

    The most recent financial report for Geovax labs, inc. (GOVX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GOVX's short-term business performance and financial health. For the latest updates on GOVX's earnings releases, visit this page regularly.

  • How much cash does GOVX have?

    At the end of the period, Geovax labs, inc. (GOVX) held Total Cash and Cash Equivalents of 5.01M, accounting for 0.74 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is GOVX's EPS continuing to grow?

    According to the past four quarterly reports, Geovax labs, inc. (GOVX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.31. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GOVX?

    Geovax labs, inc. (GOVX)'s Free Cash Flow (FCF) for the period is -6.21M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 33.33% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of GOVX?

    The latest valuation data shows Geovax labs, inc. (GOVX) has a Price-To-Earnings (PE) ratio of -0.55 and a Price/Earnings-To-Growth (PEG) ratio of 0.03. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.

GOVX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1